Skip to main content
Canadian Family Physician logoLink to Canadian Family Physician
. 1989 Oct;35:2087–2090.

Primary and Secondary Drug Treatment of Myocardial Infarction

JW Warnica
PMCID: PMC2280935  PMID: 21249088

Abstract

The management of myocardial infarction has been revolutionized during the last few years. Based on a better understanding of the physiopathology of infarction, aggressive intervention with drug therapy has made great reductions in both mortality and morbidity possible. Early reperfusion of the infarct-related artery with such thrombolytic agents as streptokinase or recombinant tissue plasminogen activator may decrease acute mortality by up to 50%. New uses for older drugs, such as acetylsalicylic acid and nitroglycerin, give them a primary role in acute myocardial infarction. β-Blocking drugs, when given in the early and later phases of myocardial infarction, also clearly reduce mortality and morbidity. Combining early reperfusion and adjunctive therapy with ASA, nitrates, and β-blockers will surely become accepted as the most effective method of treating the pain, limiting the damage, and preventing the complications of myocardial infarction.

Keywords: cardiovascular disease, myocardial infarction, pharmaceutic therapy

Full text

PDF
2087

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gibson R. S., Boden W. E., Theroux P., Strauss H. D., Pratt C. M., Gheorghiade M., Capone R. J., Crawford M. H., Schlant R. C., Kleiger R. E. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med. 1986 Aug 14;315(7):423–429. doi: 10.1056/NEJM198608143150704. [DOI] [PubMed] [Google Scholar]
  2. Herlitz J., Hjalmarson A., Waagstein F. Treatment of pain in acute myocardial infarction. Br Heart J. 1989 Jan;61(1):9–13. doi: 10.1136/hrt.61.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Jugdutt B. I., Warnica J. W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation. 1988 Oct;78(4):906–919. doi: 10.1161/01.cir.78.4.906. [DOI] [PubMed] [Google Scholar]
  4. Lee T. H., Weisberg M. C., Brand D. A., Rouan G. W., Goldman L. Candidates for thrombolysis among emergency room patients with acute chest pain. Potential true- and false-positive rates. Ann Intern Med. 1989 Jun 15;110(12):957–962. doi: 10.7326/0003-4819-110-12-957. [DOI] [PubMed] [Google Scholar]
  5. Yusuf S., Collins R., MacMahon S., Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988 May 14;1(8594):1088–1092. doi: 10.1016/s0140-6736(88)91906-x. [DOI] [PubMed] [Google Scholar]
  6. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES